RBC Capital Reiterates Outperform on Elevance Health, Maintains $572 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Ben Hendrix has reiterated an Outperform rating on Elevance Health (NYSE:ELV) and maintained a price target of $572.
July 20, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevance Health's stock may see positive movement as RBC Capital maintains its Outperform rating and $572 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of an Outperform rating and a high price target by RBC Capital indicates strong confidence in Elevance Health's performance, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100